Nevirapine hepatotoxicity: Implications of risk factors

American Journal of Pharmacology and Toxicology

Volumn 8, Issue 2, 2013, Pages 51-63

  Adikwu, Elias ^a   Deo, Oputiri ^b   Precious Geoffrey, Oru Bo ^b   Akuegbe Enimeya, D ^b  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

^b Department of Pharm Tech   (Nigeria)

Author keywords

Hepatotoxicity; Nevirapine; Risk factors

Indexed keywords

EFAVIRENZ; HLA ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION; LIVER TOXICITY; MIXED INFECTION; NONHUMAN; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SKIN TOXICITY;

EID: 84878643164     PISSN: 15574962     EISSN: 15574970     Source Type: Journal    
DOI: 10.3844/ajptsp.2013.51.63     Document Type: Review

References (83)

1. Aaron, E., M.C. Kempf, S. Criniti, E. Tedaldi and E. Gracelt et al., 2010. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLOS, 9: 12617-12617.
2. Adaramoye, O.A., I.A. Adedara and E.O. Farombi, 2012. Possible ameliorative effects of kolaviron against reproductive toxicity in sub-lethally whole body gamma-irradiated rats. Exp. Toxicol. Pathol., 64: 379-85.PMID: 21036568
3. Adewale, B.D., D.J. Dumet, I. Vroh-Bi, O.B. Kehinde and D.K. Ojo et al., 2012. Morphological diversity analysis of African yam bean and prospects for utilization in germplasm conservation and breeding. Genet. Resources Crop Evolut., 59: 927-936. DOI:10.1007/s10722-011-9734-1
4. Almond, L.M., M. Boffito, P.G. Hoggard, S. Bonora and R. Raiteri et al., 2004a. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res. Hum. Retroviruses, 20: 716-722.PMID: 15307917
5. Almond, L.M., M. Boffito, P.G. Hoggard, S. Bonora and R. Raiteri et al., 2004b. AIDS research and human. Retroviruses, 20: 716-722.PMID: 15307917
6. Antela, A., A. Ocampo, R. Gomez and M.J. Lopez et al. 2010. Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: Results of the TOSCANA study. HIV Clin. Trials, 11: 11-17.
7. Bacq, Y., O. Zarka and J.F. Brechot, 1996. Liver function tests in normal pregnancy: A prospective study of 103 pregnant women and 103 matched controls. Hepatology, 23: 1030-1034.PMID: 8621129
8. Baylor, M.S. and R. Johann-Liang, 2004. Hepatotoxicity associated with nevirapine use. J. Acquir. Immune. Defic. Syndr., 35: 538-539.PMID: 15021321
9. Bera, E., D. Naidoo and M. Williams, 2012. Maternal deaths following nevirapine-based antiretroviral therapy. Sout. Afr. J. HIV Med., 13: 196-197.
10. Bera, I. and R. Mia, 2012. Safety of nevirapine in HIVinfected pregnant women initiating antiretroviral therapy at higher CD4 counts: A systematic review and meta-analysis. South Afr. Med. J., 102: 855-859. DOI: 10.7196/samj.5700
11. Berenguer, J., J.M. Bellon, P. Miralles and E. Alvarez, 2008. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis., 46: 137-143. DOI: 10.1086/524080
12. Bershoft-Matcha, S.J., L.M. Mundy and J.V. Henry, 2004. Nevirapine, pregnancy and adverse events. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections, Feb. 8-11, Moscone West, San Francisco, CA.
13. Black, V. and H. Rees, 2008. Incidence of nevirapineassociated hepatitis in an antenatal clinic. South Med. J., 98: 116-118.PMID: 18350206
14. Bonacini, M., 2004. Liver injury during highly active antiretroviral therapy: The effect of hepatitis C coinfection. Clin. Infect. Dis., 38: 104-108. DOI: 10.1086/381453
15. Bonnet, F., S. Lawson-Ayayi, R. Thiebaut, R. Ramanampamonjy and D. Lacoste et al., 2002. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin. Infect. Dis., 35: 1231-1237. DOI: 10.1086/343046
16. Bottaro, E.G., M.J. Huberman, M.C. Iannella, F.A. Vesperoni and P.G. Scapellato et al., 2010. Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. J. Int. Assoc. Phys. AIDS Care, 9: 306-312. DOI: 10.1177/1545109710376250
17. Capparelli, E.V., F. Aweeka, J. Hitti, A. Stek and C. Hu et al., 2008. Chronic administration of nevirapine during pregnancy: Impact of pregnancy on pharmacokinetics. HIV Med., 9: 214-220. DOI: 10.1111/j.1468-1293.2008.00553.x
18. Carr, A. and D.A. Cooper, 2000. Adverse effects of antiretroviral therapy. Lancet, 356: 1423-1430. DOI: 10.1016/S0140-6736(00)02854-3
19. Cecchini, D., A. Uruena, P. Trinidad, F. Vespersoni and D. Mecikovsky, 2011. HIV and pregnancy: Maternal and neonatal evolution. Med. (Buonos Alres), 71: 432-436.PMID: 22057168
20. Chng, C.L., M. Morgan, I. Hainsworth and J.G.C. Kingham, 2002. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut, 51: 876-880. DOI: 10.1136/gut.51.6.876
21. Coca, N.S., M.S. Oliveira, I. Voieta, C.M. Antunes and J.R. Lambertucci, 2010. Antituberculosis druginduced hepatotoxicity: A comparison between patients with and without human immunodeficiency virus seropositivity. Rev. Soc. Bras. Med. Trop., 43: 624-628. DOI: 10.1590/S0037-86822010000600004
22. Coffie, P., B.A. Tonwe-Gold, K. Tanon and C. Amiani. 2010. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. BMC Infect. Dis., 10: 1-10.PMID: 20576111
23. Dieterich, T.D., A.P. Robison, J. Love and O.J. Stern, 2004. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis., 38: 508-509.PMID: 14986279
24. Edwards, S.G, N. Larbalestier, P. Hay, D. Ruiter and J. Welch et al., 2001b. Experience of nevirapine use in a London cohort of HIV-infected pregnant women. HIV Med., 2: 89-91. DOI: 10.1046/j.1468-1293.2001.00059.x
25. Edwards, S.G., N. Larbalestier, P. Hay, D. Ruiter and J. Welch et al., 2001a. Experience of nevirapine use in a London cohort of HIV-infected pregnant women. HIV Med., 2: 89-91. DOI: 10.1046/j.1468-1293.2001.00059.x
26. Fagot, J.P., M. Mockenhaupt, J.N. Bouwes-Bavnick, L. Naldi and C. Viboud et al., 2001. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS, 15: 1843-1848.PMID:11579247
27. Friis-Moller, N., R. Weber, A.D. Monforte, W. El-Sadr and P. Reiss et al., 2003b. Exposure to HAART is associated with an increased risk of myocardial infarction: The D: A: D study. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections, Feb. 10-14, Boston, Mass.
28. Friis-Moller, N., R. Weber, P. Reiss, R. Thièbaut and O. Kirk et al., 2003a. DAD study group. Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral thrapy: Results from the DAD study. AIDS, 17: 1179-1193. DOI: 10.1097/00002030-200305230-00010
29. Fuping, G., L. Wei, H. Yang, Q. Zhifeng and Z. Lingyan et al., 2010. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: Multicentric observation cohort. J. Acquir. Immun. Defic. Syndr., 54: 137-142. DOI: 10.1097/QAI.0b013e3181cc5964
30. Gatnaga, H., H. Yazaki, J. Tanuma, M. Honda and I. Genka et al., 2007. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS, 21: 264-265. DOI: 10.1097/QAD.0b013e32801199d9
31. Harris, M. and J.S. Montaner, 2000. Clinical uses of nonnucleoside reverse transcriptase inhibitors. Rev. Med. Virol., 10: 217-229.PMID: 10891870
32. Heil, E.L., M.L. Townsend, K. Shipp and A. Clarke, 2010. Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients. AIDS Res. Treat., 1: 1-4. DOI:10.1155/2010/856542
33. Herlitz, L.C., S. Mohan, M.B. Stokes, J. Radhakrishnan and V.D. D'Agati et al., 2010. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological and mitochondrial abnormalities. Kidney Int., 78: 1171-1177. DOI: 10.1038/ki.2010.318
34. Hitti, J., L. Frenkel, A. Stek, S. Nachman and A. Gonzalez-Garcia et al., 2004. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J. Acquir. Immun. Defic. Syndr., 36: 772-776.PMID: 15213559
35. Jamisse, L., J. Balkus, J. Hitti, S. Gloyd and R. Manuel et al., 2007. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J. Aquir. Immun. Defficiency Synd., 1: 371-76.PMID: 17259905
36. Joao, E.C., G.A. Calvet, J.A. Menezes, M.L. Cruz and L.A. Salgado et al., 2006. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am. J. Obstet. Gynecol., 194: 199-202.PMID: 16389032
37. Knobel, H., J.M. Miro, B. Mahillo, A. Rivero and E. Ribera et al., 2004. Failure of cetirizine to prevent nevirapine-associated rash: A double-blind placebocontrolled trial for the GESIDA 26/01 Study. J. AIDS, 37: 1276-1281.PMID: 15385735
38. Kondo, W., A.A. Astori, S.K. Gomes, R.B. Fernandes and M. Sasaki et al., 2008 Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital. Rev. Bras. Ginecol. Obstet., 30: 19-24.PMID: 19142538
39. Kondo, W., E.A. Carraro, E. Prandel, J.M. Dias and J. Perini, 2007. Nevirapine-induced side effects in pregnant women: Experience of a Brazilian university hospital. Braz. J. Infect. Dis., 11: 544-548. DOI: 10.1590/S1413-86702007000600004
40. Kramer, F., A. Stek, G. Sheehan, C. Bergin and F. Mulcahy, 2004. Nevirapine tolerability in HIV infected women in pregnancy-a word of caution.
41. Labarga, P., V. Soriano, M.E. Vispo, J. Pinilla and L. Martin-Carbonero et al., 2007. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J. Infect. Dis., 196: 670-676.PMID: 17674307
42. Langlet, P., M.P. Guillaume, J. Devriendt, D. Vokaer and L. Deltenre et al., 2000. Fatal liver failure associated with nevirapine in a pregnant HIV patient: The first reported case. Gastroenterology, 118: A1461-A1461. DOI: 10.1016/S0016-5085(00)81744-8
43. Law, W.P., G.J. Dore, C.J. Duncombe, A. Mahanontharit and M.A. Boyd et al., 2003. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIVNAT Cohort, Thailand, 1996-2001. AIDS, 17: 2191-2199. DOI: 10.1097/00002030-200310170-00007
44. Lazzari, D.E., A. Leon, J.A. Arnaiz, E. Negredo and B. Clotet et al., 2008. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med., 9: 221-226. DOI: 10.1111/j.1468-1293.2008.00552.x
45. Leth, V.F., S. Andrews, B. Grinsztein, M.K. Lazanas and J.M. Lange et al., 2005. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS, 19: 463-471.PMID: 5764851
46. Littera, R., R. Littera, C. Carcassi, A. Masala and P. Piano et al., 2006. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS, 20: 1621-1626.PMID: 16868443
47. Lyons, F., S. Hopkins, B. Kelleher, A. McGeary and G. Sheehan, 2006. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med., 7: 255-260. DOI: 10.1111/j.1468-1293.2006.00369.x
48. Macias, J., V. Castellano, N. Merchante, J.A. Mira and F. Lozano et al., 2004. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS, 18: 767-774.PMID: 15075511
49. Magiolo, F., C. Arici, M. Alriodi, D. Ripamonti and G. Quinzan et al., 2007. Reasons for discontinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort. J. Antimicrob. Chemother., 59: 569-572.PMID: 17255141
50. Manfredi, R. and L. Calza, 2006. Nevirapine versus efavirenz in 742 patients: No link of liver toxicity with female sex and a baseline CD4 cell count greater than 250 cells/mL. AIDS, 20: 2233-2236.PMID: 17086066
51. Manosuthi, W., C. Athichathanabadi, S. Uttayamakul, T. Phoorisri and S. Sungkanuparph, 2007. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect. Dis., 7: 14-14. DOI: 10.1186/1471-2334-7-14
52. Marazzi, M.C., P. Germano, G. Liotta, G. Guidotti and S. Loureiro et al., 2006. Safety of nevirapinecontaining antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med., 7: 338-344.PMID: 16945080
53. Martin, A., D. Nolan, I. James, P. Cameron and J. Keller et al., 2005. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1_0101 and abrogated by low CD4+ T cell counts. AIDS, 19: 97-99.PMID: 15627041
54. Mbougua, J.B., C. Laurent, C. Kouanfack, A. Bourgeois and L. Ciaffi et al., 2010. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health, 10: 105-105.PMID: 20193053
55. McKoy, J.M., C.L. Bennett, M.H. Scheetz, V. Differding and K.K. Scarsi et al., 2009. Hepatotoxicity associated with long versus shoot-course HIV prophylactic Nevirapine use. Drug. Saf., 32: 147-158. DOI: 10.2165/00002018-200932020-00007
56. Medrano, J., P. Bairrero, P. Tuma, E. Vispo and P. Labarga et al., 2008. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev., 10: 110-115.PMID: 18615121
57. Mocroft, A., S. Staszewski, R. Weber, J. Gasiorowski and G. Panos et al., 2007. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naïve and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antiviral Ther., 12: 325-333.PMID: 17591022
58. Murphy, R. and J. Montaner, 1996. Nevirapine: A review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Invest. Drugs, 5: 1183-1199. DOI:10.1517/13543784.5.9.1183
59. Nagu, T.J., M. Kanyangarara, C. Hawkins, E. Hertmark and G. Chalamila et al., 2012. Elevated alanine aminotransferase in antiretroviral-naïve HIVinfected African patients: Magnitude and risk factors. HIV Med., 13: 541-548. DOI:10.1111/j.1468-1293.2012.01006.x
60. Natarajan, U., A. Pym, C. McDonald, S.G. Edwards and P. Hay et al., 2007. Safety of nevirapine in pregnancy. HIV Med., 8: 64-69. DOI: 10.1111/j.1468-1293.2007.00433.x
61. Ocama, P., M. Katwere, T. Piloya, J. Feld and K.C. Opio et al., 2008. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr. Health Sci., 8: 8-12.PMID: 19357726
62. Ofotokun, I., S.E. Smithson, C. Lu, K.A. Easley and J.L. Lennox, 2007. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am. J. Med. Sci., 334: 334-341. DOI: 10.1097/MAJ.0b013e31811ec780
63. Ouyang, D.W., D.E. Shapiro, M. Lu, S.B. Brogly and A.L. French et al., 2009. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS, 27: 2425-2430.PMID: 19617813
64. Peter, J.P., N. Polle, C. Zeh, R. Masabra and B. Oyaro et al. 2011. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya. J. Int. Assoc. Phys. AIDS Care, l11: 142-149. DOI: 10.1177/1545109711423445
65. Peters, P.J., J. Stringer, M.S. McConnell, W. Ratanasuwan and P. Intalapaporn et al., 2010. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. HIV Med., 11: 650-660. DOI: 10.1111/j.1468-1293.2010.00873.x
66. Phanuph, N., 2007. Toxicities from Nevirapine (NVP)- based antiretroviral regimens in pregnant women with CD4 count between 250-350 cells/mm3. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections, Feb. 25-28, Los Angeles, USA.
67. Phillips, E., S. Gutierrez and N. Jahnke, 2007. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drugnaive HIVpositive patients. AIDS, 21: 1561-1568. DOI: 10.1097/QAD.0b013e3282170a9d
68. Pilliero, P.J. and B. Purdy, 2001. Nevirapine-induced hepatitis: A case series and review of the literature. AIDS Read., 11: 379-382.PMID: 11494710
69. Pineda, J.A. and J. Macias, 2005. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J. Antimicrob. Chemot., 55: 417-419. DOI: 10.1093/jac/dkh555
70. Prakash, M., V. Poreddy, L. Tiyyagura and M. Bonacini, 2001. Jaundice and hepatocellular damage associated with nevirapine therapy. Am. J. Gastroenterol., 96: 1571-1573.PMID: 11374701
71. Saint-Marc, T., M. Partisani, I. Poizot-Martin, F. Bruno and O. Rouviere et al., 1999. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS, 13: 1359-1367.PMID: 10509567
72. Snijdewind, I.J., C. Smit, H.M. Godfried, J.F. Nellen and K. Boer et al., 2012. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. J. Infect., 64: 409-416. DOI: 10.1016/j.jinf.2011.12.012
73. Stern, J.O., P.A. Robinson, J. Love, S. Lanes and M.S. Imperiale et al., 2003. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J. Acquir. Immun. Defic. Syndr., 34: 21-33. DOI: 10.1097/00126334-200309011-00005
74. Storfer, S., J. Leith, P. Robinson, P. Piliero and D. Hall, 2005. Analysis of hepatic events within the 2NN study: Controlling for geographic region and CD4+ cell count at initiation of nevirapine therapy. Eur. AIDS Clin. Soc., 6: 254-261.
75. Sulkowski, M.S., D.L. Thomas, S.H. Mehta, R.E. Chaisson and R.D. Moore, 2002. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 35: 182-189. DOI: 10.1053/jhep.2002.30319
76. Thomas, T., P. Amornkul, J. Mwidau, R. Masaba and L. Slutsker et al., 2005. Preliminary findings: Incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trial using HAART to prevent mother-to-child HIV transmission. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections, Feb. 22-25, Boston, MA, USA.
77. Tian, W., D.A. Boggs, G. Uko, B. Banjoko and T. Adewole et al., 2003. MICA, HLA-B haplotypic variation in five population groups of sub-Saharan African ancestry. Genes. Immunity, 4: 500-505.PMID: 14551603
78. Torty, C., S. Costaralle, A. Desilvestri, E. Quiros- Roldom and G. Lapadula et al., 2007. Analysis of severe hepatic events associated with nevirapinecontaining regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug Safety, 30: 1161-1169.PMID: 18035868
79. Umar, R.A., S.W. Horsan, M.J. Ladan and I.K. Matazu, 2008. Adverse hepatic effects associated with administration of antiretroviral drugs (nevinaprine, lamivudine and stavudine to albino rat; implication for management of patient with HIV/AIDS. A. J. Biochem., 3: 19-25.
80. Vogel, M., N. Bertram, J.C. Wasmuth, C. Wyen and E. Voigt et al., 2009. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. J. Antimicrob. Chemother., 63: 988-991.PMID: 19270314
81. Wang, J., H. Kou, Q. Fu, Y. Han and Z. Qiu et al., 2011. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in chinese patients with HIV infection. PLoS ONE, 6: 26739-26739.
82. Weidle, P.J., D. Moore, J. Mermin, R. Downing and A. Kigozi et al., 2008. Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS, 22: 787-795.PMID: 18778241
83. Wolf, E., C. Koegl and T. Theobald, 2006. Nevirapineassociated hepatotoxicity: No increased risk for females or high CD4 count in a single centre HIV cohort. Proceedings of the Program and Abstracts of the 46th ICAAC, Sept. 27-30, San Francisco, CA.